According to CoinMeta, BeiGene (06160.hk) announced that its total global revenue in the third quarter of 2026 reached $1.9 billion, a year-on-year increase of 34%. Among this, Zanubrutinib (Baiyueze®) generated global revenue of $1.4 billion in the third quarter, also showing a year-on-year growth of 34%. The company has raised its full-year total revenue forecast for 2026 to between $6.9 billion and $7 billion, with operating profit expected to be between $1.2 billion and $1.3 billion, and non-operating profit expected to be between $1.9 billion and $2 billion.